67‐year‐old female, JAK2‐positive post‐ET MF with anaemia, splenomegaly and constitutional symptomsRuxolitinib and navitoclax via REFINE (NCT03222609)Symptom and spleen improvementNavitoclax dose reductions due to cytopeniasTransfusion‐dependent anaemia with iron overload requiring chelationRuxolitinib plus luspatercept/placebo via INDEPENDENCE (NCT04717414)Reduced transfusion requirementsProgression to accelerated phase so discontinued study. This evidence concerns the gene JAK2 and Splenomegaly.